Navigation Links
New Study Casts Doubt on FDA Pradaxa Conclusions
Date:6/25/2013

New York, New York (PRWEB) June 25, 2013

Chaffin Luhana LLP, a national plaintiffs-only law firm, warns heart patients that though the FDA has stated Pradaxa carries no more risk of bleeding than warfarin, a recent study may show evidence that seems to be contrary to the FDA's conclusion.

“Studies have been mixed on Pradaxa,” said Chaffin Luhana LLP co-founder Eric Chaffin, “but the risk is there, particularly because so far, we have no readily available antidote for Pradaxa bleeding. This makes any fall or accident that causes bruising in patients taking Pradaxa potentially deadly.”

According to a report by the dailyRX News Network, in March, at the American College of Cardiology Scientific Sessions, researchers from the University of Illinois at Chicago presented research that showed a high number of bleeding events in those taking Pradaxa (dabigatran) compared to warfarin. (“Does Stroke Rx Cause Excess Bleeding?” dailyRx News, March 18, 2013) The team examined reports of bleeding events submitted to the FDA through 2011-2012. Results showed that Pradaxa was the primary or secondary agent in over 4,000 bleeding events, with 638 fatalities. Warfarin was associated with only a little over 800 bleeding events, with 44 fatalities.

“The total number of bleeding-related fatalities for dabigatran have greatly exceeded warfarin,” the researchers stated. (Kevin McConeghy, et al., “Reports of Bleeding-Related Fatalities with Dabigatran and Warfarin: An Analysis Using the Food and Drug Administration Adverse Events Reporting System,” American College of Cardiology, March 10, 2013)

These results conflict with the FDA perspective recently published in the New England Journal of Medicine. (Mary Ross Southworth, et al., “Dabigatran and Postmarketing Reports of Bleeding,” NEJM, April 4, 2013) There, the FDA acknowledged that they had received many reports of bleeding events associated with Pradaxa after the approval of the drug in October 2010—more than those associated with warfarin.

The number of reports conflicted with the controlled trial that supported Pradaxa’s approval, which showed that both drugs “conferred a similar risk of bleeding.” The FDA suggested that the higher number of reports could be due to the fact that Pradaxa was new to the market, as when they used insurance-claim data and administrative data from the FDA Mini-Sentinel database, they “found that bleeding rates associated with dabigatran use during the period of interest did not appear to be higher than those associated with warfarin.”

According to the Institute for Safe Medicine Practices “Quarter Watch,” published January 9, 2013, an analysis of hemorrhage cases for anticoagulant drugs, including Pradaxa, warfarin (Coumadin), and rivaroxaben (Xarelto), Pradaxa bleeding events were about five times more likely than warfarin to result in death. (ISMP “Quarter Watch,” January 9, 2013)

Chaffin Luhana LLP has a long and successful history of protecting the rights of those injured by potentially dangerous drugs like Pradaxa. Partners Eric Chaffin and Roopal Luhana represent high-profile cases in federal and state courts across the country, and provide new online resource centers for clients and the public. To date, Mr. Chaffin and Ms. Luhana along with co-counsel have been involved in recovering over $1 billion for injured consumers. Both have been named to the prestigious New York Metro Super Lawyers list, and though unable to guarantee results, the firm has a distinguished track record of success and is highly committed to each case.

If you or a loved one has suffered an injury after taking Pradaxa, contact Chaffin Luhana LLP for a free and confidential case review at 1-888-480-1123, or visit their website at http://www.chaffinluhana.com.

CONTACT
Eric T. Chaffin, Esq.
CHAFFIN LUHANA LLP
600 Third Ave., 12th Floor
New York, New York 10016

Toll Free Telephone: (888) 480-1123
Toll Free Fax: (888) 499-1123

Attorney Advertising. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Read the full story at http://www.prweb.com/releases/2013/6/prweb10755124.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Study Suggests Vaccine May Help Kids With Brain Cancer
2. Study reveals how cancer drug causes diabetic-like state
3. Coffee Drinking in Pregnancy Wont Lead to Sleepless Baby: Study
4. Lower GI problems plague many with rheumatoid arthritis, Mayo Clinic study finds
5. Veggies Like Broccoli, Cabbage May Help Fight Breast Cancer: Study
6. No Added Cancer Risk From Hip Replacement Materials: Study
7. Reported Decline in U.S. Pneumonia Deaths May Be False: Study
8. Early Study Finds Some Promise for Lung Cancer Vaccine
9. Narcissists Often Ace Job Interviews, Study Finds
10. Sexual objectification of female artists in music videos exists regardless of race, MU study finds
11. Soy may alleviate hot flashes in menopause, large-scale study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical ... Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. ... honor of Morris F. Collen, a pioneer in the field of medical informatics, this ...
(Date:10/12/2017)... ... 2017 , ... Dr. Parsa Mohebi, the Los Angeles based ... the newly revamped Cosmetic Town journal section, featuring articles written by ... as Follicular Unit Extraction (FUE). , Dr. Mohebi says “I enjoy ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the ... – Miles by Moonlight to raise money for the American Heart Association Heart Walk. ... , Teams will work together to keep their treadmills moving for 5 hours. Treadmills ...
(Date:10/12/2017)... ... October 12, 2017 , ... In the United States, single-family ... some states—like New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and California—the average ... extremely low property-tax rates, which contributes to the relatively lower cost of living ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... enhanced Pepper Flow promotional review platform at the Promotional Review Committee Compliance ... capabilities help marketers streamline the medical, legal, and regulatory review (MLR) process ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... 2017  NDS received FDA 510(k) clearance in May 2017 for ... stand specifically designed for endoscopy environments. An innovative secondary monitor solution, ... solution to support the improvement of patient outcomes, procedural efficiency, and ... ... ...
(Date:10/7/2017)... --  Provista, a proven leader in the supply ... power, today announced a new resource area on Provistaco.com ... is the online home for case studies, articles on ... releases, slideshows and events. ... at their fingertips, viewers can also watch short videos ...
(Date:10/4/2017)... Oct. 4, 2017  South Korean-based healthcare product Development ... aide "cprCUBE" on Kickstarter. The device will educate the ... arrests with better efficiency compared to the dated and ... feedback on efficacy of the compression for a more ... a goal to raise $5,000. ...
Breaking Medicine Technology: